Brief: Cytokinetics And Royalty Pharma Announce Expanded Strategic Funding Collaboration Of Up To $575 Mln

Royalty Pharma

22/05/2024 21:03

May 22 (Reuters) - Cytokinetics Inc  CYTK.O :
    * CYTOKINETICS AND ROYALTY PHARMA ANNOUNCE EXPANDED
STRATEGIC
FUNDING COLLABORATION TOTALING UP TO $575 MILLION TO SUPPORT
COMMERCIAL LAUNCH OF AFICAMTEN AND TO ADVANCE RESEARCH AND
DEVELOPMENT PIPELINE
    * CYTOKINETICS INC -  ROYALTY PHARMA WILL NOW RECEIVE 4.5%
UP TO
$5.0 BILLION OF ANNUAL NET SALES OF AFICAMTEN AND 1% ABOVE $5.0
BILLION OF ANNUAL NET SALES
    * CYTOKINETICS INC - CYTOKINETICS WILL RECEIVE $100 MILLION
IN
UPFRONT CAPITAL TO FUND A CONFIRMATORY PHASE 3 CLINICAL TRIAL OF
OMECAMTIV MECARBIL

Source text for Eikon:  ID:nGNXQMXfw 
Further company coverage:  CYTK.O 

 ((reuters.briefs@thomsonreuters.com;))